Shanghai Pharmaceuticals Holding Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic a… Read more
Shanghai Pharmaceuticals Holding Co. Ltd (SHPMF) - Total Liabilities
Latest total liabilities as of March 2025: $140.57 Billion USD
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co. Ltd (SHPMF) has total liabilities worth $140.57 Billion USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Pharmaceuticals Holding Co. Ltd - Total Liabilities Trend (1994–2024)
This chart illustrates how Shanghai Pharmaceuticals Holding Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Pharmaceuticals Holding Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Pharmaceuticals Holding Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Derwent London PLC
PINK:DWVYF
|
USA | $1.67 Billion |
|
MAG Silver Corp
NYSE MKT:MAG
|
USA | $23.53 Million |
|
Bestechnic (Shanghai) Co. Ltd. A
SHG:688608
|
China | CN¥568.95 Million |
|
Bel Fuse B Inc
NASDAQ:BELFB
|
USA | $416.53 Million |
|
Alliance Resource Partners LP
NASDAQ:ARLP
|
USA | $993.57 Million |
|
Mineral Resources Limited
PINK:MALRF
|
USA | $7.71 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down Shanghai Pharmaceuticals Holding Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Pharmaceuticals Holding Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Pharmaceuticals Holding Co. Ltd (1994–2024)
The table below shows the annual total liabilities of Shanghai Pharmaceuticals Holding Co. Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $137.47 Billion | +4.42% |
| 2023-12-31 | $131.65 Billion | +9.58% |
| 2022-12-31 | $120.13 Billion | +15.10% |
| 2021-12-31 | $104.37 Billion | +10.51% |
| 2020-12-31 | $94.44 Billion | +7.76% |
| 2019-12-31 | $87.64 Billion | +8.94% |
| 2018-12-31 | $80.45 Billion | +47.15% |
| 2017-12-31 | $54.67 Billion | +19.08% |
| 2016-12-31 | $45.91 Billion | +13.25% |
| 2015-12-31 | $40.54 Billion | +21.94% |
| 2014-12-31 | $33.24 Billion | +21.72% |
| 2013-12-31 | $27.31 Billion | +16.87% |
| 2012-12-31 | $23.37 Billion | +7.76% |
| 2011-12-31 | $21.69 Billion | +33.17% |
| 2010-12-31 | $16.28 Billion | +157.08% |
| 2009-12-31 | $6.33 Billion | +11.80% |
| 2008-12-31 | $5.67 Billion | +9.65% |
| 2007-12-31 | $5.17 Billion | +12.05% |
| 2006-12-31 | $4.61 Billion | +5.53% |
| 2005-12-31 | $4.37 Billion | -0.75% |
| 2004-12-31 | $4.40 Billion | +9.33% |
| 2003-12-31 | $4.03 Billion | +18.34% |
| 2002-12-31 | $3.40 Billion | +37.51% |
| 2001-12-31 | $2.47 Billion | -2.94% |
| 2000-12-31 | $2.55 Billion | +15.61% |
| 1999-12-31 | $2.21 Billion | +16.23% |
| 1998-12-31 | $1.90 Billion | +518.28% |
| 1997-12-31 | $306.95 Million | -1.92% |
| 1996-12-31 | $312.95 Million | +17.26% |
| 1995-12-31 | $266.88 Million | +18.53% |
| 1994-12-31 | $225.16 Million | -- |